pembrolizumab Jul 6, 2022 Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials Jun 22, 2022 Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer Premium May 25, 2022 Oncotelic Gets FDA Permission to Start Phase II Trial of TGF-B Inhibitor, Keytruda in Mesothelioma May 25, 2022 NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold May 18, 2022 City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers Apr 29, 2022 Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors Apr 28, 2022 Merck Q1 Revenues Increase 50 Percent Driven by Keytruda Apr 19, 2022 PDS Biotechnology Nets $1.2M Through NJ Economic Development Program to Advance Oncology Candidates Apr 6, 2022 Iovance Biotherapeutics Receives Positive FDA Feedback Supporting Lifileucel BLA Submission Apr 4, 2022 European Commission Approves Immunocore's T-Cell Receptor Therapy Kimmtrak in Uveal Melanoma Mar 28, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in PD-L1-Expressing Cervical Cancers Mar 25, 2022 EMA's CHMP Issues Positive Recommendation for Merck's Keytruda in Specific MSI-H/dMMR Tumors Mar 25, 2022 Study Shows TIL-Based Biomarker Could Predict Checkpoint Inhibitor Response in NSCLC Premium Mar 22, 2022 FDA Approves Merck's Keytruda for MSI-H, dMMR Endometrial Cancer With Roche CDx Mar 10, 2022 Oxford BioDynamics Gathering Real-World Data on Checkpoint Inhibitor Response Predictor Premium Mar 10, 2022 Microbiotica Advancing Bacterial Signature to Improve Immunotherapy Response, Patient Selection Premium Mar 8, 2022 UK's NICE Recommends Against Merck's Keytruda, Chemo Combo for Advanced PD-L1-Positive TNBC Feb 22, 2022 FDA Approves Foundation Medicine Test as CDx for Merck's Keytruda to Identify MSI-H Solid Tumors Feb 15, 2022 Mayo Clinic Exploring PDS Biotech's PDS0101, Merck's Keytruda in HPV-Associated Oropharyngeal Cancer Feb 11, 2022 Selected TIL Therapy Shows Promise in Metastatic Breast Cancer Patients in NCI Pilot Study Premium Load More Breaking News FDA Approves Taiho Oncology's Lytgobi for FGFR2-Rearranged Bile Duct Cancer Gladstone Institute Joins With Parker Institute on New Center to Study CRISPR-Based Cell Therapies Meliora Therapeutics Raises $11M in Seed Financing In Brief This Week:Â Verismo Therapeutics, Fore Biotherapeutics, Merck, Caris Life Sciences Tumor-Only Sequencing Found to Overestimate Mutational Burden in Non-European Patients Atara Biotherapeutics to Net $30M From Pierre Fabre for European Tab-Cel Approval
